ОбзорГрафикНовостиTraderScreen

Morgan Stanley Knock-Out ZLAB/  DE000MG2HE36  /

Stuttgart
28.10.2024  15:36:17 Изменение- Бид22:00:36 Предложение22:00:36 Базовый актив Цена исполнения Дата истечения Тип опциона
2.08EUR - -
Величина цены спроса: -		 -
Величина цены предложения: -		 Zai Lab Ltd 10.5411 - 31.12.2078 Call
GlobeNewswire 07.11.2023 Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
GlobeNewswire 26.10.2023 Zai Lab Announces Participation in November Investor Conferences
GlobeNewswire 18.10.2023 Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7,...
GlobeNewswire 18.09.2023 Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injec...
GlobeNewswire 30.08.2023 Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patien...
GlobeNewswire 29.08.2023 Zai Lab Announces Participation in September Investor Conferences
GlobeNewswire 23.03.2022 Zai Lab Announces Change to Virtual Extraordinary General Meeting of Shareholders to be Held on Marc...
GlobeNewswire 21.03.2022 Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gyne...
GlobeNewswire 15.03.2022 Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer
GlobeNewswire 01.03.2022 Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021
GlobeNewswire 17.02.2022 Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China
GlobeNewswire 15.02.2022 Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2022
GlobeNewswire 07.02.2022 Zai Lab Announces Upcoming Presentation at February Investor Conference
GlobeNewswire 12.01.2022 Zai Lab Announces First Patient Treated in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor ...
GlobeNewswire 29.12.2021 Zai Lab Announces Upcoming Presentations at January Investor Conferences
GlobeNewswire 22.12.2021 Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Ne...
GlobeNewswire 18.12.2021 Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgar...
GlobeNewswire 16.12.2021 China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Commu...
GlobeNewswire 03.12.2021 Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for F...
GlobeNewswire 30.11.2021 Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-...
GlobeNewswire 23.11.2021 Zai Lab Announces Upcoming Presentations at December Investor Conferences
GlobeNewswire 22.11.2021 Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors
GlobeNewswire 16.11.2021 Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Ef...
GlobeNewswire 15.11.2021 Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Ef...
GlobeNewswire 11.11.2021 Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Ef...